Top US
Cholesterol Meds
Blogs about Cholesterol Meds
- Study could slash 20 off Mercks cholesterol meds FiercePharma »
As November 16 nears, hardcore pharmawatchers are biting their nails. Thats when researchers will unveil the latest trial of Mercks cholesterol meds Vytorin and Zetia. As you know, the study in... Read more...
- Statin Drugs Used To Lower Cholesterol May Also Reduce H1N1 ... »
Statin Drugs Used To Lower Cholesterol May Also Reduce H1N1 Related Deaths.
- Dr. Roger Blumenthal Comparing Zetia and Niacin Cholesterol ... »
Vitals Spotlight Dr. Roger Blumenthal Comparing Zetia and Niacin Cholesterol Medications.
- Popular Cholesterol Drugs Shown Harmful and Ineffective Baby ... »
Popular Cholesterol Drugs Shown Harmful and Ineffective and very expensive. So, who is taking them I would say that the majority of users are Baby.
- CNBC.com »
A new study is putting Mercks cholesterol drugs under pressure today, reports CNBCs Mike Huckman, with Ken Frazier, Merck Global Human Health president. Add this share icon. Advertisement. Previous Video: NYSE Morning Preview ...
- Cholesterol Drugs Zetia and Vytorin produce no benefits eFitnessNow »
Two cholesterol drugs, Zetia and its sister drug, Vytorin, which are used by millions of Americans are now the subject of concern once again. Doctors are now.
Cholesterol Success Plus?120 Tabs? - only $29.72
![]()
Speak with your doctor about whether the use of Cholesterol Success may replace the need to take any other cholesterol lowering product.?. Cholesterol Success can be taken alone, or in combination with a diet and exercise program. Additionally, Cholesterol Success can be used by those who do not have elevated LDL cholesterol levels, but who wish to be proactive in maintaining healthy cholesterol levels. »
Selected NewsNo standards, no mandates to test, limit meds in water (Texarkana Gazette)EDITORS NOTEDespite evidence that traces of pharmaceuticals can be found in much of Americas drinking water supplies, government and suppliers are doing little, according to this final part of an Associated Press investigative series. Read more |
No video yet.